Add office photos
Engaged Employer
Cipla

4.1
based on 7.2k Reviews
Video summary
Proud winner of ABECA 2024 - AmbitionBox Employee Choice Awards
Company Overview
Associated Companies
Company Locations
Working at Cipla
Company Summary
Cipla is a leading Global Pharmaceutical Company that ensures access to quality & affordable medicines through various products across various therapeutic categories.
Overall Rating
4.1/5
based on 7.2k reviews

5% above
industry average

Highly rated for
Salary, Skill development, Company culture
Work Policy

Work from office
72% employees reported

Alternate Saturday off
37% employees reported

Flexible timing
56% employees reported

Within city
39% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
598 employees reported
Health insurance
570 employees reported
Office cab/shuttle
272 employees reported
Professional degree assistance
195 employees reported
View all benefits
About Cipla
Founded in1935 (90 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
Websitecipla.com
Primary Industry
Other Industries

View in video summary
At Cipla, we constantly work towards ensuring access to high quality and affordable medicines to support patients in need. Which is why, we have been trusted by health care professionals and patients across geographies for the last 8 decades. Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
AmbitionBox Best Places to Work in India Awards
Best of the best, rated by employees
Cipla won India’s Largest Employee Choice Awards in Large Companies Category.
#2 Top Rated Pharma Company
Share
Cipla Ratings
based on 7.2k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.6k
4
1.9k
3
867
2
316
1
486
Category Ratings
4.0
Salary
4.0
Skill development
3.9
Company culture
3.9
Work-life balance
3.8
Work satisfaction
3.7
Job security
3.6
Promotions
Cipla is rated 4.1 out of 5 stars on AmbitionBox, based on 7.2k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Cipla
based on 6.8k reviews
4.0
Rated by 726 Women
Rated 3.8 for Work-life balance and 3.8 for Company culture
4.1
Rated by 6.1k Men
Rated 4.0 for Salary and 4.0 for Skill development
Work Policy at Cipla
based on 914 reviews in last 6 months
Work from office
72%
Hybrid
23%
Permanent work from home
5%
Cipla Reviews
Top mentions in Cipla Reviews
+ 5 more
Compare Cipla with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 4.1/5 based on 7.2k reviews | 4.1/5 based on 6.2k reviews | 4.0/5 based on 7.1k reviews | 4.1/5 based on 6.3k reviews |
Highly Rated for | Skill development Salary Work-life balance | Salary Skill development Job security | Skill development Company culture Work-life balance | Skill development Company culture Work-life balance |
Critically Rated for | No critically rated category | No critically rated category | Promotions | No critically rated category |
Primary Work Policy | Work from office 72% employees reported | Work from office 82% employees reported | Work from office 75% employees reported | Work from office 86% employees reported |
Rating by Women Employees | 4.0 Good rated by 726 women | 4.0 Good rated by 399 women | 4.0 Good rated by 801 women | 4.0 Good rated by 382 women |
Rating by Men Employees | 4.1 Good rated by 6.1k men | 4.1 Good rated by 5.2k men | 4.1 Good rated by 5.9k men | 4.1 Good rated by 5.7k men |
Job security | 3.7 Good | 3.9 Good | 3.5 Good | 3.7 Good |
View more
Cipla Salaries
Cipla salaries have received with an average score of 4.0 out of 5 by 7.2k employees.
Deputy Manager
(1.1k salaries)
Unlock
₹5.3 L/yr - ₹18.6 L/yr
Therapy Manager
(511 salaries)
Unlock
₹2.3 L/yr - ₹7.1 L/yr
Area Business Manager
(498 salaries)
Unlock
₹4.4 L/yr - ₹12 L/yr
Regional Business Manager
(351 salaries)
Unlock
₹8 L/yr - ₹20 L/yr
Medical Representative
(310 salaries)
Unlock
₹1.3 L/yr - ₹7 L/yr
Production Officer
(242 salaries)
Unlock
₹1.2 L/yr - ₹9.8 L/yr
Territory Manager
(240 salaries)
Unlock
₹1.8 L/yr - ₹8 L/yr
Area Sales Manager
(193 salaries)
Unlock
₹4.5 L/yr - ₹11.3 L/yr
Maintenance Engineer
(192 salaries)
Unlock
₹1.2 L/yr - ₹5 L/yr
Trainee
(189 salaries)
Unlock
₹1.2 L/yr - ₹4 L/yr
Cipla Interview Questions
Interview questions by designation
Top Cipla interview questions and answers
Get interview-ready with top interview questions
Cipla Jobs
Popular Designations Cipla Hires for
Current Openings
Cipla News
View all
Sensex snaps 7-day rally; HUL weighs on FMCG stocks
- HUL emerged as the biggest laggard, weighing on FMCG stocks.
- Nifty fell 82 points to close at 24246, ending the seven-day winning streak.
- Top gainers included IndusInd Bank, UltraTech Cement, Grasim Industries, Dr. Reddy’s Laboratories, and Cipla.
- Nifty Pharma index gained nearly 1%, while other sectors ended in the red.
HinduBusinessLine | 24 Apr, 2025

Stock Market Today: All You Need To Know Going Into Trade On April 21
- India's benchmark equity indices closed higher for the third consecutive session on Thursday, with NSE Nifty 50 rising 1.77% and BSE Sensex going up by 1.96% to record their best week in four years.
- Foreign portfolio investors continued to be net buyers of Indian equities while domestic institutional investors were net sellers on Thursday.
- Several notable earnings reports included HDFC Bank, ICICI Bank, Yes Bank, HDFC Life Insurance, Infosys, and Tata Elxsi, among others.
- Stocks to watch included Jubilant Pharmova, Shree Cement, Biocon, BHEL, Vedanta, Cipla, Divi’s Laboratories, and National Fertilizers, among others.
- In trading tweaks, price band changes were noted for Diffusion Engineers, while Nifty April Futures saw an increase and a fall in open interest.
- The Indian rupee appreciated by 31 paise against the US dollar, closing at 85.38, supported by foreign inflows and stable market sentiment.
- Key developments in bulk deals and trading tweaks were observed for Coforge, Fusion Finance, Hathway Cable & Datacom, and others in the market.
- Overall, the stock market witnessed positive movements, with key indices performing well and notable corporate updates impacting investor sentiment.
- Various sectors and companies reported financial results, strategic investments, product launches, and regulatory approvals, influencing market dynamics.
- The market closed amidst a positive outlook, with key highlights including the rupee's appreciation, trading cues, and notable moves in the stock market.
- In the midst of several corporate actions and market developments, investors remained attentive to earnings reactions, stock movements, and upcoming board meetings.
Bloomberg Quint | 21 Apr, 2025

Stock Recommendations Today: IndiGo, Ajanta Pharma, NTPC On Brokerages' Radar
- Motilal Oswal upgraded IndiGo with a higher target of Rs 6,550, while Jefferies initiated coverage on Ajanta Pharma and maintained a positive outlook on NTPC.
- Brokerage firms issued fresh stock calls on IndiGo, Ajanta Pharma, and NTPC, reflecting key market insights.
- Jefferies expects more banks to announce deposit rate cuts following HDFC Bank and SBI.
- Goldman Sachs upgraded its year-end gold price forecast to $3,700, citing a hedge against rising recession risk.
- Investec raised the target price for Home First Finance and highlighted its competitive strength post-capital raise.
- Citi's global equity strategy includes upgrades for Japan and the UK, downgrade for the US, and preference for tech and financial sectors.
- Nomura, HSBC, and Macquarie provided insights on stocks like Cipla, PI Industries, NTPC, HDFC Bank, and L&T.
- UBS expects gold to rally to $3,500 this year as a safe haven amid geopolitical and economic uncertainty.
- Morgan Stanley lowered its GDP growth estimate for financial year 2026 but remains positive on Indian equity outperformance.
- Citi maintains a Buy rating on Vodafone Idea, anticipating a fundraise catalyst and an upgrade in credit rating.
Bloomberg Quint | 15 Apr, 2025

Markets rebound sharply as Sensex gains over 1,000 points amid global relief rally
- Markets rebounded sharply as Sensex gained over 1,000 points amid global relief rally.
- Positive global cues and anticipation of bilateral agreements with the US contributed to the market recovery.
- NSE top gainers included Jio Financial Services, Shriram Finance, BEL, Adani Enterprises, and Cipla.
- Market breadth was positive with the Nifty Midcap 100 and Nifty Next 50 outperforming the benchmark indices.
HinduBusinessLine | 8 Apr, 2025

Nifty 50 Top Gainers And One Loser On April 8: Power Grid Only Laggard, JFS, Cipla Gain
- The Indian stock market recovered the losses that it made Monday following a severe crash that saw the benchmark indices declining over 5%.
- Nifty 50 closed 1.69% up at 22,535 and Sensex closed 1.49% higher at 74,227.
- The top gainers for Tuesday's trade were Jio Financial Services Ltd., Shriram Finance Ltd., Cipla Ltd., Bharat Electronics Ltd. and Eicher Motors Ltd.
- The only stock that closed the trading session with losses in Tuesday's trade was Power Grid Corp.
Bloomberg Quint | 8 Apr, 2025

Sun Pharma, Divi's Labs & Cipla Shares Drag Pharma Stocks To Over 10-Month Low
- Sun Pharma, Divi's Labs & Cipla Shares Drag Pharma Stocks To Over 10-Month Low
- The market-cap of Nifty Pharma company declined Rs 40,476 crore to Rs 15.62 lakh crore as of 9:27 a.m.
- The NSE Nifty Pharma index has extended losses to a second day due to concerns over tariffs from the US.
- Sun Pharmaceutical Industries Ltd. and Divi's Laboratories contribute the most to the decline in the index.
Bloomberg Quint | 7 Apr, 2025

Trump threatens tariffs on pharma: Industry braces for tariffs, counter-tariffs and bilaterals
- US President Donald Trump has threatened to impose tariffs on pharmaceuticals, which has caused concern within the industry.
- The announcement comes after country-specific tariffs were recently announced, which initially exempted pharmaceuticals.
- Companies in the industry are uncertain about the impact and are considering different tariff scenarios and strategies.
- Stock prices of companies with significant US revenues, such as Aurobindo Pharma and Cipla, have dropped in response to the news.
HinduBusinessLine | 4 Apr, 2025

Nifty prediction today – April 4, 2025: Index in bear grip
- The Nifty index is in a bear grip with a bearish bias.
- ONGC and Cipla are the top losers, down over 6% each, while HDFC Bank is the top gainer with a 2.1% increase.
- Most sectors are down, with Nifty Metal and Nifty Pharma being the top losers.
- The April futures of Nifty 50 opened lower and currently trading at 23,000, down 1.4%.
HinduBusinessLine | 4 Apr, 2025

Indian pharma stocks plummet over 4% amid tariff threats from Trump
- Indian pharma stocks plunged over 4% following tariff threats from Donald Trump.
- Trump mentioned that the pharma tariffs will be announced soon.
- The pharma index was the top sectoral loser on the Nifty 50, down by about 1.2%.
- All constituents of the pharma index, including Sun Pharma, Dr Reddy's, and Cipla, traded in the red.
HinduBusinessLine | 4 Apr, 2025
Nifty Top Gainers, Losers On April 3: From TCS, HCLTech To Power Grid, Sun Pharma
- Sun Pharmaceutical Industries Ltd., Power Grid Corp. and Cipla Ltd. were the top gainers on the NSE Nifty 50.
- Tata Consultancy Services Ltd., HCL Technologies Ltd. and Tech Mahindra Ltd. were the worst performers.
- The NSE Nifty 50 closed 0.35% lower at 23,250.10 and the BSE Sensex ended 0.42% down at 76,295.36.
- US President Donald Trump imposing heavy tariffs on India and the world affected the benchmark equity indices negatively.
Bloomberg Quint | 3 Apr, 2025

Powered by
Cipla Subsidiaries
Cipla Health
4.1
• 328 reviews
Report error
Compare Cipla with

Sun Pharmaceutical Industries
4.0

Aurobindo Pharma
4.0

Intas Pharmaceuticals
4.1

Hetero
3.9

Viatris
4.2

Alembic Pharmaceuticals
4.0

Abbott
4.1

Ipca Laboratories
3.9

Glenmark Pharmaceuticals
3.9

Alkem Laboratories
3.9

Torrent Pharmaceuticals
3.9

Mankind Pharma
3.9

MSN Laboratories
3.7

Ajanta Pharma
4.0

Akums Drugs & Pharmaceuticals Limited
4.4

GlaxoSmithKline Pharmaceuticals
4.1

Pfizer
3.9

DIVI'S Laboratories
3.7

Wockhardt
3.9

Teva Pharmaceuticals
4.0
Contribute & help others!
You can choose to be anonymous
Write a review
Share interview
Contribute salary
Add office photos
Companies Similar to Cipla

Dr. Reddy's
Clinical Research, Pharma
4.0
• 7.1k reviews

Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.4k reviews

Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6.2k reviews

Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 6.1k reviews

Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 5k reviews

Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.6k reviews

Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.2k reviews

Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.2k reviews

Ipca Laboratories
Pharma
3.9
• 3.1k reviews

Glenmark Pharmaceuticals
Pharma
3.9
• 3.1k reviews
Cipla FAQs
When was Cipla founded?
Cipla was founded in 1935. The company has been operating for 90 years primarily in the Pharma sector.
Where is the Cipla headquarters located?
Cipla is headquartered in Mumbai, Maharashtra. It operates in 2 cities such as Mumbai, Hyderabad / Secunderabad. To explore all the office locations, visit Cipla locations.
How many employees does Cipla have in India?
Cipla currently has more than 25,000+ employees in India. Marketing & Communication department appears to have the highest employee count in Cipla based on the number of reviews submitted on AmbitionBox.
Does Cipla have good work-life balance?
Cipla has a Work-Life Balance Rating of 3.9 out of 5 based on 7,100+ employee reviews on AmbitionBox. 77% employees rated Cipla 4 or above, while 23% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Cipla work-life balance reviews for more details
Is Cipla good for career growth?
Career growth at Cipla is rated fairly well, with a promotions and appraisal rating of 3.6. 77% employees rated Cipla 4 or above, while 23% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Cipla promotions/appraisals reviews for more detailed insights.
What are the pros of working in Cipla?
Working at Cipla offers several advantages that make it an appealing place for employees. The company is highly rated for salary & benefits, skill development and company culture, based on 7,100+ employee reviews on AmbitionBox.
Recently Viewed
DESIGNATION
Paralegal
494 salaries
JOBS
PERMAWELD
3 jobs
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app